Molecular Partners to hold three poster presentations at AACR 2025
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: GlobeNewswire
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, IL. Details of the presentations: MP0712, the first
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted RadiotherapeuticsGlobeNewswire
- Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.MarketBeat
- Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual MeetingGlobeNewswire
MOLN
Analyst Actions
- 12/8/25 - JP Morgan
MOLN
Sec Filings
- 12/8/25 - Form 6-K
- 11/12/25 - Form 6-K
- 10/30/25 - Form 6-K
- MOLN's page on the SEC website